Neogen Corporation (NEOG) Current Ratio
- Current ratio · latest quarter: Value 3.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.82× | Current assets / current liabilities. $604.60M ÷ $158.20M ≈ 3.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 604.60M USD | Assets, Current |
| Current obligations | 158.20M USD | Liabilities, Current |
| Cash and equivalents | 185.50M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 146.80M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 144.30M USD | Inventory, Net |
| Payables | 79.10M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $604.60M | $158.20M | $185.50M | (m) | $146.80M | $144.30M | $79.10M | $0.00 | 3.82× |
| 2026-02-28 | $590.00M | $150.60M | $159.90M | (m) | $137.10M | $161.70M | $75.20M | (m) | 3.92× |
| 2025-11-30 | $574.58M | $147.05M | $145.34M | (m) | $132.00M | $162.77M | $63.04M | (m) | 3.91× |
| 2025-08-31 | $524.06M | $146.21M | $138.88M | (m) | $138.46M | $193.41M | $76.60M | (m) | 3.58× |
| 2025-05-31 | $576.90M | $174.00M | $129.00M | (m) | $153.40M | $190.80M | $79.60M | $19.30M | 3.32× |
| 2025-02-28 | $551.71M | $141.20M | $127.70M | $0.00 | $160.07M | $205.44M | $72.24M | (m) | 3.91× |
| 2024-11-30 | $570.45M | $151.19M | $140.23M | $0.00 | $164.09M | $198.27M | $79.57M | (m) | 3.77× |
| 2024-08-31 | $540.65M | $122.69M | $120.48M | $0.00 | $167.64M | $198.60M | $61.46M | (m) | 4.41× |
| 2024-05-31 | $589.23M | $154.32M | $170.61M | $325.00K | $173.00M | $189.27M | $83.06M | $2.45M | 3.82× |
| 2024-02-29 | $602.47M | $157.84M | $161.44M | $7.01M | $173.59M | $182.39M | $89.75M | $2.52M | 3.82× |
| 2023-11-30 | $624.37M | $176.61M | $205.76M | $24.50M | $150.50M | $160.53M | $112.18M | $2.57M | 3.54× |
| 2023-08-31 | $583.79M | $138.13M | $178.83M | $60.42M | $137.67M | $140.69M | $90.21M | $2.64M | 4.23× |
| 2023-05-31 | $585.93M | $145.47M | $163.24M | $82.33M | $153.25M | $133.81M | $76.67M | (m) | 4.03× |
| 2023-02-28 | $555.37M | $107.16M | $67.13M | $116.08M | $146.39M | $143.86M | $60.49M | (m) | 5.18× |
| 2022-11-30 | $643.33M | $152.56M | $100.00M | $176.34M | $142.71M | $136.07M | $79.25M | (m) | 4.22× |
| 2022-08-31 | $607.91M | $67.00M | $107.10M | $240.61M | $93.11M | $129.04M | $27.00M | (m) | 9.07× |
| 2022-05-31 | $626.80M | $77.84M | $44.47M | $336.58M | $99.67M | $122.31M | $34.61M | (m) | 8.05× |
| 2022-02-28 | $609.63M | $65.71M | $42.88M | $335.56M | $92.98M | $113.39M | $23.55M | (m) | 9.28× |
| 2021-11-30 | $611.20M | $62.67M | $51.12M | $338.13M | $92.50M | $107.09M | $34.22M | (m) | 9.75× |
| 2021-08-31 | $609.12M | $50.76M | $71.28M | $329.60M | $87.29M | $102.11M | $22.41M | (m) | 12.00× |
| 2021-05-31 | $591.45M | $53.60M | $75.60M | $305.49M | $91.82M | $100.70M | $23.90M | (m) | 11.03× |
| 2021-02-28 | $555.30M | $45.94M | $73.48M | $279.87M | $87.24M | $99.27M | $23.26M | (m) | 12.09× |
| 2020-11-30 | $578.43M | $44.59M | $113.87M | $276.90M | $79.93M | $92.53M | $20.70M | (m) | 12.97× |
| 2020-08-31 | $556.70M | $46.44M | $60.95M | $306.54M | $77.69M | $97.57M | $22.54M | (m) | 11.99× |
| 2020-05-31 | $537.41M | $48.49M | $66.27M | $277.40M | $84.68M | $95.05M | $25.65M | (m) | 11.08× |
| 2020-02-29 | $514.88M | $39.13M | $50.77M | $277.15M | $80.69M | $89.24M | $18.99M | (m) | 13.16× |
| 2019-11-30 | $500.18M | $38.79M | $66.41M | $247.19M | $85.38M | $86.41M | $19.57M | (m) | 12.89× |
| 2019-08-31 | $473.55M | $40.43M | $56.29M | $234.73M | $79.11M | $87.68M | $18.34M | (m) | 11.71× |
| 2019-05-31 | $449.53M | $38.25M | $41.69M | $225.84M | $82.58M | $85.99M | $19.06M | (m) | 11.75× |
| 2019-02-28 | $422.60M | $34.27M | $93.58M | $153.10M | $80.01M | $84.87M | $18.95M | (m) | 12.33× |
| 2018-11-30 | $414.29M | $38.76M | $101.58M | $139.38M | $82.28M | $79.47M | $20.55M | (m) | 10.69× |
| 2018-08-31 | $396.12M | $39.22M | $97.22M | $129.19M | $78.08M | $78.77M | $20.89M | (m) | 10.10× |
| 2018-05-31 | $375.79M | $38.69M | $83.07M | $127.74M | $79.09M | $76.00M | $20.75M | (m) | 9.71× |
| 2018-02-28 | $352.20M | $37.29M | $82.07M | $110.09M | $73.21M | $77.51M | $19.65M | (m) | 9.44× |
| 2017-11-30 | $339.94M | $37.95M | $64.42M | $111.41M | $74.86M | $73.71M | $17.43M | (m) | 8.96× |
| 2017-08-31 | $310.93M | $38.32M | $58.46M | $101.53M | $66.34M | $73.41M | $16.66M | (m) | 8.11× |
| 2017-05-31 | $292.96M | $36.00M | $77.57M | $66.07M | $68.58M | $73.14M | $16.24M | (m) | 8.14× |
| 2017-02-28 | $276.77M | $34.72M | $59.88M | $64.70M | $67.37M | $75.40M | $17.07M | (m) | 7.97× |
| 2016-11-30 | $288.40M | $33.87M | $86.30M | $55.81M | $64.90M | $71.68M | $17.29M | (m) | 8.52× |
| 2016-08-31 | $268.61M | $32.64M | $76.19M | $53.04M | $59.35M | $69.84M | $17.97M | (m) | 8.23× |
| 2016-05-31 | $248.23M | $28.60M | $55.26M | $52.54M | $67.65M | $64.37M | $15.80M | (m) | 8.68× |
| 2016-02-29 | $254.94M | $27.78M | $66.86M | $58.30M | $56.16M | $65.45M | $15.40M | (m) | 9.18× |
| 2015-11-30 | $250.48M | $31.23M | $71.38M | $51.64M | $57.60M | $61.48M | $20.68M | (m) | 8.02× |
| 2015-08-31 | $235.36M | $26.90M | $42.33M | $68.63M | $59.04M | $56.11M | $14.76M | (m) | 8.75× |
| 2015-05-31 | $231.19M | $25.46M | $66.06M | $48.10M | $59.21M | $51.60M | $13.69M | (m) | 9.08× |
| 2015-02-28 | $217.35M | $26.55M | $57.48M | $44.66M | $52.89M | $55.10M | $10.59M | (m) | 8.19× |
| 2014-11-30 | $205.75M | $24.12M | $49.06M | $45.25M | $52.11M | $53.50M | $11.31M | (m) | 8.53× |
| 2014-08-31 | $201.17M | $24.48M | $53.46M | $34.64M | $51.69M | $55.09M | $13.00M | (m) | 8.22× |
| 2014-05-31 | $188.75M | $24.97M | $40.67M | $35.82M | $51.90M | $51.18M | $13.40M | (m) | 7.56× |
| 2014-02-28 | $175.97M | $24.53M | $43.28M | $25.53M | $48.07M | $51.86M | $11.77M | (m) | 7.17× |
| 2013-11-30 | $178.86M | $23.29M | $43.61M | $35.48M | $45.80M | $47.33M | $11.36M | (m) | 7.68× |
| 2013-08-31 | $177.91M | $22.84M | $43.61M | $40.77M | $43.65M | $43.76M | $11.65M | (m) | 7.79× |
| 2013-05-31 | $168.45M | $17.72M | $50.03M | $35.34M | $38.74M | $38.31M | $9.21M | (m) | 9.51× |
| 2013-02-28 | $160.07M | $22.57M | $48.86M | $25.70M | $38.69M | $41.08M | $9.95M | (m) | 7.09× |
| 2012-11-30 | $152.57M | $18.32M | $41.31M | $29.53M | $37.59M | $38.38M | $8.42M | (m) | 8.33× |
| 2012-08-31 | $152.74M | $18.97M | $44.48M | $30.02M | $37.69M | $35.01M | $9.33M | (m) | 8.05× |
| 2012-05-31 | $143.94M | $19.98M | $49.05M | $19.60M | $35.65M | $34.99M | $10.76M | (m) | 7.20× |
| 2012-02-29 | $136.19M | $17.44M | $42.70M | $18.64M | $34.33M | $36.31M | $7.71M | (m) | 7.81× |
| 2011-11-30 | $130.42M | $18.41M | $36.97M | $18.63M | $31.87M | $36.42M | $9.61M | (m) | 7.08× |
| 2011-08-31 | $124.22M | $18.25M | $22.03M | $29.32M | $32.67M | $34.22M | $9.80M | (m) | 6.81× |
| 2011-05-31 | $122.50M | $17.80M | $35.84M | $20.24M | $28.63M | $31.99M | $8.52M | (m) | 6.88× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |